Ian Read - Pfizer Chairman, CEO and Chairman of Executive Committee
| PFE Stock | USD 26.27 0.05 0.19% |
Chairman
Mr. Ian C. Read is Executive Chairman of the Board of Pfizer Inc. He was Chairman of the Board and Chief Executive Officer from December 2011 to December 2018. President and Chief Executive Officer from December 2010 until December 2011. Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business unitsPrimary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Chair of the Pfizer Foundation. Director of KimberlyClark Corporationrationration.Mr. Read brings over 35 years of business, operating and leadership experience to the Board. His extensive knowledge of the biopharmaceutical industry in general, and Pfizers worldwide biopharmaceutical business in particular, provides crucial insight to our Board on the companys strategic planning and operations. Mr. Read provides advice and counsel to management and the Board, and the combination of his knowledge of the business and his leadership skills makes his role as Executive Chairman optimal at this time. In addition, his experience as a member of another public company board provides him with an enhanced perspective on issues applicable to public companies. since 2018.
| Age | 64 |
| Tenure | 6 years |
| Address | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 |
| Phone | 212 733 2323 |
| Web | https://www.pfizer.com |
Pfizer Management Efficiency
The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to 0.02. In addition to that, Return On Capital Employed is expected to decline to 0.02. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Daniel ODay | Gilead Sciences | 60 | |
| Kenneth Frazier | Merck Company | 67 | |
| Alex Gorsky | Johnson Johnson | 64 | |
| Giovanni Caforio | Bristol Myers Squibb | 56 | |
| Robert Michael | AbbVie Inc | 54 | |
| Lamberto Andreotti | Bristol Myers Squibb | 64 | |
| Richard Gonzalez | AbbVie Inc | 70 | |
| Robert Bradway | Amgen Inc | 61 | |
| Ashley McEvoy | Johnson Johnson | 50 | |
| Jennifer Taubert | Johnson Johnson | 60 | |
| John Lechleiter | Eli Lilly and | 61 | |
| Thibaut Mongon | Johnson Johnson | 51 | |
| Jorge Mesquita | Johnson Johnson | 56 | |
| Joaquin Duato | Johnson Johnson | 61 | |
| Paulus Stoffels | Johnson Johnson | 57 | |
| Carlos Alban | AbbVie Inc | 55 | |
| Robert JD | Merck Company | 57 | |
| John Martin | Gilead Sciences | 65 | |
| Sandra Peterson | Johnson Johnson | 58 | |
Management Performance
| Return On Equity | 0.0235 | ||||
| Return On Asset | 0.0155 |
Pfizer Inc Leadership Team
Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller | ||
| Douglas Lankler, Executive Vice President General Counsel | ||
| Shantanu Narayen, Lead Independent Director | ||
| Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical | ||
| Susan DesmondHellmann, Independent Director | ||
| Stephen Sanger, Independent Director | ||
| Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer | ||
| Aamir Malik, Executive Vice President Chief Business Innovation Officer | ||
| Christopher Stevo, Senior Vice President and Chief Investor Relations Officer | ||
| Geno Germano, Group President of Global Innovative Pharma Bus. | ||
| Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations | ||
| William Carapezzi, Executive Vice President - Global Business Services and Transformation | ||
| Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President | ||
| Mikael MD, Chief Development | ||
| Payal Becher, Chief VP | ||
| James Quincey, Independent Director | ||
| Charles Hill, Executive Vice President - Worldwide Human Resources | ||
| Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business | ||
| Payal Sahni, Executive Vice President, Chief People Experience Officer | ||
| Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Angela Hwang, Group President - Pfizer Biopharmaceuticals Group | ||
| Mike Mcdermott, Executive Vice President Chief Global Supply Officer | ||
| Kathrin Jansen, Senior Vice President - Vaccine Research & Development | ||
| John Young, Group President - Pfizer Innovative Health and Angela Hwang | ||
| Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | ||
| Dawn Rogers, Chief Human Resource Officer, Executive Vice President | ||
| Helen Hobbs, Independent Director | ||
| James Smith, Independent Director | ||
| Christopher CFA, VP Officer | ||
| Dennis Ausiello, Independent Director | ||
| Michael Mcdermott, Executive Vice President Chief Global Supply Officer | ||
| Francesca DeMartino, Chief Officer | ||
| Frances Fergusson, Independent Director | ||
| Gordon Loh, Senior Vice President Corporate Audit | ||
| Wyllie Cornwell, Independent Director | ||
| Suzanne Johnson, Independent Director | ||
| David Denton, Chief VP | ||
| Alexander Mackenzie, Executive Vice President Chief Development Officer | ||
| DVM DVM, Chairman CEO | ||
| William Gray, Independent Director | ||
| Sally Susman, Chief Corporate Affairs Officer, Executive Vice President | ||
| Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply | ||
| Susan Hockfield, Independent Director | ||
| Freda LewisHall, Executive Vice President Chief Medical Officer | ||
| Albert DVM, Chairman CEO | ||
| Dan Littman, Independent Director | ||
| Ian Read, Chairman, CEO and Chairman of Executive Committee | ||
| James Kilts, Independent Director | ||
| Don Cornwell, Independent Director | ||
| Andreas Panayiotou, Global Officer | ||
| Joseph Echevarria, Independent Director | ||
| Scott Gottlieb, Independent Director | ||
| Ronald Blaylock, Independent Director | ||
| Michael Goettler, Group President - Pfizer Upjohn |
Pfizer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0235 | ||||
| Return On Asset | 0.0155 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | (0.50) % | ||||
| Current Valuation | 211.54 B | ||||
| Shares Outstanding | 5.66 B | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 69.94 % | ||||
| Number Of Shares Shorted | 65 M | ||||
| Price To Earning | 9.48 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Dividend Share 1.64 | Earnings Share 0.37 | Revenue Per Share 10.366 | Quarterly Revenue Growth (0.41) |
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.